Hemogenyx Pharmaceuticals Plc
(“Hemogenyx” or the “Company”)
Posting of Annual Report
& Notice of Annual General Meeting
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2017 (“2017 Annual Report”), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company’s website:
https://hemogenyx.com/investors/annual-and-half-year-reports/default.aspx
The 2017 Annual Report will be posted to shareholders today.
The AGM is to be held on 27 June 2018 at 11am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London, EC4M 7RD.
Enquiries:
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
| Sir Marc Feldmann, Executive Chairman | ||
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
| Christian Dennis | ||
| Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 | |
| Damon Heath, Erik Woolgar | ||
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
| Lucy Williams, Duncan Vasey | ||
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
| US Media enquiries | ||
| Lowell Goodman | Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com | |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.
END
MSCFAMRTMBMMBIP